ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Research Report 2025
Published Date: June 2025
|
Report Code: QYRE-Auto-31A5669
Home | Market Reports | Health| Health Conditions| Cancer
Global Mono Antibody mAb for HER2 Positive Advanced Breast Cancer Market Insights Forecast to 2028
BUY CHAPTERS

Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Research Report 2025

Code: QYRE-Auto-31A5669
Report
June 2025
Pages:79
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Roche
Boc Sciences
LGM Pharma
Biotechnica Pharma Global
KinBio
Merck

Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market

Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market

The global market for Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
These antibodies are used to treat metastatic (spread) breast cancer. It is effective against tumors that overexpress the HER2/neu protein.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer.
The Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market size, estimations, and forecasts are provided in terms of sales volume (Kilograms) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Report

Report Metric Details
Report Name Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market
CAGR 5%
Segment by Type
  • Pertuzumab
  • Trastuzumab
Segment by Application
  • Combination Therapy
  • Mono Therapy
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Roche, BOC Sciences, LGM Pharma, Biotechnica Pharma Global, KinBio, Merck
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market report?

Ans: The main players in the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market are Roche, BOC Sciences, LGM Pharma, Biotechnica Pharma Global, KinBio, Merck

What are the Application segmentation covered in the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market report?

Ans: The Applications covered in the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market report are Combination Therapy, Mono Therapy

What are the Type segmentation covered in the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market report?

Ans: The Types covered in the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market report are Pertuzumab, Trastuzumab

1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Overview
1.1 Product Definition
1.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Type
1.2.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Value Comparison by Type (2024 VS 2031)
1.2.2 Pertuzumab
1.2.3 Trastuzumab
1.3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Application
1.3.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Value by Application (2024 VS 2031)
1.3.2 Combination Therapy
1.3.3 Mono Therapy
1.4 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Estimates and Forecasts
1.4.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue 2020-2031
1.4.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales 2020-2031
1.4.3 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Competition by Manufacturers
2.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Manufacturers (2020-2025)
2.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer, Product Type & Application
2.7 Global Key Manufacturers of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer, Date of Enter into This Industry
2.8 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Competitive Situation and Trends
2.8.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Players Market Share by Revenue
2.8.3 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Scenario by Region
3.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Region: 2020-2031
3.2.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Region: 2020-2025
3.2.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Region: 2026-2031
3.3 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Region: 2020-2031
3.3.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Region: 2020-2025
3.3.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Region: 2026-2031
3.4 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Facts & Figures by Country
3.4.1 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country (2020-2031)
3.4.3 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Facts & Figures by Country
3.5.1 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country (2020-2031)
3.5.3 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Facts & Figures by Region
3.6.1 Asia Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Region (2020-2031)
3.6.3 Asia Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Facts & Figures by Country
3.7.1 Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country (2020-2031)
3.7.3 Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Facts & Figures by Country
3.8.1 Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country (2020-2031)
3.8.3 Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Type (2020-2031)
4.1.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Type (2020-2025)
4.1.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Type (2026-2031)
4.1.3 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Type (2020-2031)
4.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2020-2031)
4.2.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2020-2025)
4.2.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2026-2031)
4.2.3 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Type (2020-2031)
4.3 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Price by Type (2020-2031)
5 Segment by Application
5.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Application (2020-2031)
5.1.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Application (2020-2025)
5.1.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Application (2026-2031)
5.1.3 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Application (2020-2031)
5.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2020-2031)
5.2.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2020-2025)
5.2.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2026-2031)
5.2.3 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Application (2020-2031)
5.3 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 BOC Sciences
6.2.1 BOC Sciences Company Information
6.2.2 BOC Sciences Description and Business Overview
6.2.3 BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales, Revenue and Gross Margin (2020-2025)
6.2.4 BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Portfolio
6.2.5 BOC Sciences Recent Developments/Updates
6.3 LGM Pharma
6.3.1 LGM Pharma Company Information
6.3.2 LGM Pharma Description and Business Overview
6.3.3 LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales, Revenue and Gross Margin (2020-2025)
6.3.4 LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Portfolio
6.3.5 LGM Pharma Recent Developments/Updates
6.4 Biotechnica Pharma Global
6.4.1 Biotechnica Pharma Global Company Information
6.4.2 Biotechnica Pharma Global Description and Business Overview
6.4.3 Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Portfolio
6.4.5 Biotechnica Pharma Global Recent Developments/Updates
6.5 KinBio
6.5.1 KinBio Company Information
6.5.2 KinBio Description and Business Overview
6.5.3 KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales, Revenue and Gross Margin (2020-2025)
6.5.4 KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Portfolio
6.5.5 KinBio Recent Developments/Updates
6.6 Merck
6.6.1 Merck Company Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Portfolio
6.6.5 Merck Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Industry Chain Analysis
7.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Production Mode & Process Analysis
7.4 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales and Marketing
7.4.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Channels
7.4.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Distributors
7.5 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Customer Analysis
8 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Dynamics
8.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Industry Trends
8.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Drivers
8.3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Challenges
8.4 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Roche
Boc Sciences
LGM Pharma
Biotechnica Pharma Global
KinBio
Merck
List of Tables
 Table 1. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales (Kilograms) of Key Manufacturers (2020-2025)
 Table 5. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Average Price (US$/Gram) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer, Product Type & Application
 Table 12. Global Key Manufacturers of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Region (2020-2025) & (Kilograms)
 Table 18. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Region (2020-2025)
 Table 19. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Region (2026-2031) & (Kilograms)
 Table 20. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Region (2026-2031)
 Table 21. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Region (2020-2025)
 Table 23. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Region (2026-2031)
 Table 25. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country (2020-2025) & (Kilograms)
 Table 27. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country (2026-2031) & (Kilograms)
 Table 28. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country (2020-2025) & (Kilograms)
 Table 32. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country (2026-2031) & (Kilograms)
 Table 33. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Region (2020-2025) & (Kilograms)
 Table 37. Asia Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Region (2026-2031) & (Kilograms)
 Table 38. Asia Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country (2020-2025) & (Kilograms)
 Table 42. Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country (2026-2031) & (Kilograms)
 Table 43. Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country (2020-2025) & (Kilograms)
 Table 47. Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country (2026-2031) & (Kilograms)
 Table 48. Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales (Kilograms) by Type (2020-2025)
 Table 51. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales (Kilograms) by Type (2026-2031)
 Table 52. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Type (2020-2025)
 Table 53. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Type (2026-2031)
 Table 54. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Type (2020-2025)
 Table 57. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Type (2026-2031)
 Table 58. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Price (US$/Gram) by Type (2020-2025)
 Table 59. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Price (US$/Gram) by Type (2026-2031)
 Table 60. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales (Kilograms) by Application (2020-2025)
 Table 61. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales (Kilograms) by Application (2026-2031)
 Table 62. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Application (2020-2025)
 Table 63. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Application (2026-2031)
 Table 64. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Application (2020-2025)
 Table 67. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Application (2026-2031)
 Table 68. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Price (US$/Gram) by Application (2020-2025)
 Table 69. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Price (US$/Gram) by Application (2026-2031)
 Table 70. Roche Company Information
 Table 71. Roche Description and Business Overview
 Table 72. Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales (Kilograms), Revenue (US$ Million), Price (US$/Gram) and Gross Margin (2020-2025)
 Table 73. Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product
 Table 74. Roche Recent Developments/Updates
 Table 75. BOC Sciences Company Information
 Table 76. BOC Sciences Description and Business Overview
 Table 77. BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales (Kilograms), Revenue (US$ Million), Price (US$/Gram) and Gross Margin (2020-2025)
 Table 78. BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product
 Table 79. BOC Sciences Recent Developments/Updates
 Table 80. LGM Pharma Company Information
 Table 81. LGM Pharma Description and Business Overview
 Table 82. LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales (Kilograms), Revenue (US$ Million), Price (US$/Gram) and Gross Margin (2020-2025)
 Table 83. LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product
 Table 84. LGM Pharma Recent Developments/Updates
 Table 85. Biotechnica Pharma Global Company Information
 Table 86. Biotechnica Pharma Global Description and Business Overview
 Table 87. Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales (Kilograms), Revenue (US$ Million), Price (US$/Gram) and Gross Margin (2020-2025)
 Table 88. Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product
 Table 89. Biotechnica Pharma Global Recent Developments/Updates
 Table 90. KinBio Company Information
 Table 91. KinBio Description and Business Overview
 Table 92. KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales (Kilograms), Revenue (US$ Million), Price (US$/Gram) and Gross Margin (2020-2025)
 Table 93. KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product
 Table 94. KinBio Recent Developments/Updates
 Table 95. Merck Company Information
 Table 96. Merck Description and Business Overview
 Table 97. Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales (Kilograms), Revenue (US$ Million), Price (US$/Gram) and Gross Margin (2020-2025)
 Table 98. Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product
 Table 99. Merck Recent Developments/Updates
 Table 100. Key Raw Materials Lists
 Table 101. Raw Materials Key Suppliers Lists
 Table 102. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Distributors List
 Table 103. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Customers List
 Table 104. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Trends
 Table 105. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Drivers
 Table 106. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Challenges
 Table 107. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Restraints
 Table 108. Research Programs/Design for This Report
 Table 109. Key Data Information from Secondary Sources
 Table 110. Key Data Information from Primary Sources
 Table 111. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer
 Figure 2. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Type: 2024 & 2031
 Figure 4. Pertuzumab Product Picture
 Figure 5. Trastuzumab Product Picture
 Figure 6. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Application: 2024 & 2031
 Figure 8. Combination Therapy
 Figure 9. Mono Therapy
 Figure 10. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size (2020-2031) & (US$ Million)
 Figure 12. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales (2020-2031) & (Kilograms)
 Figure 13. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Average Price (US$/Gram) & (2020-2031)
 Figure 14. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Report Years Considered
 Figure 15. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Share by Manufacturers in 2024
 Figure 16. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Share by Manufacturers in 2024
 Figure 17. Global 5 and 10 Largest Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Players: Market Share by Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer in 2024
 Figure 18. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 19. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 20. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Country (2020-2031)
 Figure 21. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Country (2020-2031)
 Figure 22. U.S. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 23. Canada Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Country (2020-2031)
 Figure 25. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Country (2020-2031)
 Figure 26. Germany Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. France Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. U.K. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Italy Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Russia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Asia Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Region (2020-2031)
 Figure 32. Asia Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Region (2020-2031)
 Figure 33. China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. South Korea Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. India Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Australia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Taiwan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Indonesia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Thailand Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Malaysia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Philippines Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Type (2020-2031)
 Figure 55. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Price (US$/Gram) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Application (2020-2031)
 Figure 58. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Price (US$/Gram) by Application (2020-2031)
 Figure 59. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

Global HER2 Antibody Market Research Report 2025
Global ERBB2 Antibody Market Research Report 2024
Drugs for HR HER2 Advanced Breast Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global HER2 Targeted Therapy Market Research Report 2024
Global HER 2 Targeted Drugs for Breast Cancer Market Research Report 2024
Global Herceptin Trastuzumab Market Research Report 2024
Trastuzumab Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
HER 2 Negative Breast Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Trastuzumab Market Research Report 2025
Global HER2 Positive Breast Cancer Market Research Report 2024
Global HER2 Inhibitors Market Research Report 2024
Global Antibodies in Oncology Market Research Report 2024
Trastuzumab Monoclonal Antibody Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Targeted Drug HER2 Inhibitors for NSCLC Market Research Report 2024
Global HER2 Human Epidermal Growth Factor Receptor 2 Antibody Market Research Report 2024
HER2 Testing Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global HER2 Assay Kit Market Research Report 2024
Global Anti HER2 Therapy Market Research Report 2025
Global Monoclonal Antibody Drugs for Cancer Market Research Report 2024
Global Herceptin Biosimilar Market Insights Forecast to 2030

RELATED REPORTS

Global Fixation Device for Radiotherapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4H16852
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Group A Streptococcus for Injection Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-37K16619
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Boron Neutron Capture Therapy System Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-30U16301
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Radioactive Glass Microsphere Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-2G16953
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions